Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Mahner

Showing results (351-360 of 455) with videos related to

Pageof 46
Sort By:
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Gynecologic Oncology|October 16, 2012
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortiumAndreas Melmer, Linda Fineder, Claudia Lamina, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 13, 2022
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cellsThomas Kolben, Mareike Mannewitz, Carolin Perleberg, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|January 12, 2025
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiativeLisa Hirschberg, Franziska Henze, Kerstin Paradies, et al.
International Journal of Cancer|October 29, 2011
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancerFrederik Marmé, Thomas Hielscher, Sarah Hug, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
Annals of Surgical Oncology|October 12, 2012
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluationChristina Fotopoulou, Rongyu Zang, Murat Gultekin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2016
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
Archives of Gynecology and Obstetrics|December 5, 2020
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMUElena Sultova, C Benedikt Westphalen, Andreas Jung, et al.
Pageof 46

Showing results (351-360 of 455) with videos related to

Sort By:
Pageof 46
Frontiers in Oncology|September 26, 2019
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 ConsortiumIsabelle Ray-Coquard, Ioana Braicu, Regina Berger, et al.
Gynecologic Oncology|October 16, 2012
Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer--a study by the OVCAD consortiumAndreas Melmer, Linda Fineder, Claudia Lamina, et al.
Cellular Oncology (Dordrecht, Netherlands)|September 13, 2022
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cellsThomas Kolben, Mareike Mannewitz, Carolin Perleberg, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|January 12, 2025
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiativeLisa Hirschberg, Franziska Henze, Kerstin Paradies, et al.
International Journal of Cancer|October 29, 2011
Fibroblast growth factor receptor 4 gene (FGFR4) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancerFrederik Marmé, Thomas Hielscher, Sarah Hug, et al.
International Journal of Cancer|July 5, 2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patientsKonstantina Panoutsopoulou, Margaritis Avgeris, Paraskevi Magkou, et al.
Annals of Surgical Oncology|October 12, 2012
Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluationChristina Fotopoulou, Rongyu Zang, Murat Gultekin, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 23, 2016
Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7)Philipp Harter, Jalid Sehouli, Alexander Reuss, et al.
BMC Cancer|April 5, 2013
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortiumDietmar Pils, Dan Tong, Gudrun Hager, et al.
Archives of Gynecology and Obstetrics|December 5, 2020
NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMUElena Sultova, C Benedikt Westphalen, Andreas Jung, et al.
Pageof 46